CA3020666A1 - Methods and kits for the diagnosis and risk stratification of patients with ischemia - Google Patents

Methods and kits for the diagnosis and risk stratification of patients with ischemia Download PDF

Info

Publication number
CA3020666A1
CA3020666A1 CA3020666A CA3020666A CA3020666A1 CA 3020666 A1 CA3020666 A1 CA 3020666A1 CA 3020666 A CA3020666 A CA 3020666A CA 3020666 A CA3020666 A CA 3020666A CA 3020666 A1 CA3020666 A1 CA 3020666A1
Authority
CA
Canada
Prior art keywords
apo
lectin
levels
glycosylated
ischemia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3020666A
Other languages
English (en)
French (fr)
Inventor
Lina Badimon Maestro
Judit Cubedo Rafols
Teresa Padro Capmany
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Científicas
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Original Assignee
Consejo Superior de Investigaciones Científicas
Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior de Investigaciones Científicas, Fundacio Institut de Recerca de lHospital de La Santa Creu i Sant Pau filed Critical Consejo Superior de Investigaciones Científicas
Publication of CA3020666A1 publication Critical patent/CA3020666A1/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/38—Post-translational modifications [PTMs] in chemical analysis of biological material addition of carbohydrates, e.g. glycosylation, glycation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA3020666A 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia Pending CA3020666A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382167.1A EP3232200A1 (en) 2016-04-12 2016-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia
EP16382167.1 2016-04-12
PCT/EP2017/058768 WO2017178521A1 (en) 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia

Publications (1)

Publication Number Publication Date
CA3020666A1 true CA3020666A1 (en) 2017-10-19

Family

ID=56008566

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3020666A Pending CA3020666A1 (en) 2016-04-12 2017-04-12 Methods and kits for the diagnosis and risk stratification of patients with ischemia

Country Status (15)

Country Link
US (1) US11486884B2 (enExample)
EP (2) EP3232200A1 (enExample)
JP (1) JP7075894B2 (enExample)
KR (1) KR102344344B1 (enExample)
CN (1) CN109154620B (enExample)
AU (1) AU2017251355A1 (enExample)
BR (1) BR112018070971A2 (enExample)
CA (1) CA3020666A1 (enExample)
ES (1) ES2979390T3 (enExample)
IL (1) IL262245B (enExample)
MA (1) MA44658A (enExample)
MX (1) MX2018012580A (enExample)
RU (1) RU2750035C2 (enExample)
SG (1) SG11201808820QA (enExample)
WO (1) WO2017178521A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022506108A (ja) * 2018-10-23 2022-01-17 グリカルディアル ダイアグノスティクス エセ. エレ. グリコシル化ApoJに特異的な抗体およびその使用
JP2022510403A (ja) * 2018-12-05 2022-01-26 グリカルディアル ダイアグノスティクス エセ. エレ. 虚血傷害および虚血再灌流傷害の予防および/または治療のための方法および組成物
KR102158726B1 (ko) 2019-04-17 2020-09-22 한림대학교 산학협력단 Itpr3 유전자 업스트림의 유전자간 영역을 포함하는 지연성 허혈 진단용 dna 메틸화 마커 조성물
KR102281657B1 (ko) 2019-12-23 2021-07-26 한림대학교 산학협력단 지연성 허혈 진단을 위한 cdhr5 유전자 과메틸화 마커
KR102281644B1 (ko) 2019-12-23 2021-07-23 한림대학교 산학협력단 지연성 허혈 진단을 위한 insr 유전자 과메틸화 마커
KR102312534B1 (ko) 2019-12-31 2021-10-13 한림대학교 산학협력단 뇌척수액 유래 미토콘드리아 마커를 이용한 지연성 허혈 진단 방법
KR102318236B1 (ko) 2020-02-18 2021-10-26 한림대학교 산학협력단 혈중 코펩틴의 농도를 이용한 지연성 뇌허혈 진단 방법
KR102336507B1 (ko) 2020-02-21 2021-12-06 한림대학교 산학협력단 국소뇌산소포화도를 이용한 지연성 뇌허혈 진단 방법
KR102369155B1 (ko) 2020-07-07 2022-02-28 한림대학교 산학협력단 근적외선 분광분석법을 이용한 지연성 뇌허혈 진단 방법
KR102473349B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kifap3 유전자 과메틸화 마커
KR102496589B1 (ko) 2020-09-11 2023-02-03 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 vhl 유전자 과메틸화 마커
KR102473350B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 racgap1 유전자 과메틸화 마커
KR102473348B1 (ko) 2020-09-11 2022-12-05 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 kif3a 유전자 과메틸화 마커
KR102477500B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 oprm1 유전자 과메틸화 마커
KR102477501B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 alb 유전자 저메틸화 마커
KR102477502B1 (ko) 2020-09-15 2022-12-14 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 il5 유전자 저메틸화 마커
KR102466956B1 (ko) 2020-11-05 2022-11-11 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 dapk1 바이오마커
KR102398533B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 뇌척수액 마이토파지 마커
KR102398534B1 (ko) 2020-11-05 2022-05-13 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 bnip3l 바이오마커
KR102470789B1 (ko) 2020-11-05 2022-11-25 한림대학교 산학협력단 지연성 뇌허혈 진단을 위한 pink1 바이오마커
CN113462744B (zh) * 2021-05-24 2023-06-23 中国药科大学 N-乙酰葡萄糖胺作为标志物在制备诊断缺血性脑中风试剂中的应用
KR102865129B1 (ko) 2021-08-06 2025-09-26 에이치앤비지노믹스 주식회사 지능형 오믹스 기반 개인별 맞춤형 복잡질환 발병 위험도 정보 제공 방법 및 장치

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6140045A (en) 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
CA2301634A1 (en) * 1997-07-15 1999-01-28 Pradeep Ghosh Determining alcohol intake using sialic acid/apo j
US6197599B1 (en) 1998-07-30 2001-03-06 Guorong Chin Method to detect proteins
WO2005107491A2 (en) * 2004-05-05 2005-11-17 Northeastern University Multi-lectin affinity chromatography and uses thereof
CN102695716B (zh) * 2009-07-14 2016-03-02 独立行政法人产业技术综合研究所 肝病病情指标糖链标记物
ES2364169B1 (es) 2010-02-09 2012-07-10 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (Titular al 50%) Uso de las isoformas de apo j como biomarcadores de lesión tisular.
EP2400304A1 (en) 2010-06-22 2011-12-28 Centro de Investigación Cooperativa En Biomateriales ( CIC biomaGUNE) Method for the characterization of intermolecular interactions
JP2012107932A (ja) 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Clusterin蛋白質による脳梗塞の検査方法
ES2907068T3 (es) 2015-04-30 2022-04-21 Idexx Lab Inc Detección específica de isoformas de clusterina
CN107957498A (zh) * 2016-10-18 2018-04-24 厦门德馨尚品医疗科技有限公司 一种含有载脂蛋白j的试剂盒及其在临床诊断中的应用

Also Published As

Publication number Publication date
CN109154620B (zh) 2022-03-08
AU2017251355A1 (en) 2018-11-08
EP3232200A1 (en) 2017-10-18
MA44658A (fr) 2019-02-20
WO2017178521A1 (en) 2017-10-19
KR102344344B1 (ko) 2021-12-28
BR112018070971A2 (pt) 2019-01-29
KR20190008216A (ko) 2019-01-23
EP3443353A1 (en) 2019-02-20
RU2018139780A (ru) 2020-05-12
ES2979390T3 (es) 2024-09-25
US11486884B2 (en) 2022-11-01
JP7075894B2 (ja) 2022-05-26
RU2018139780A3 (enExample) 2020-07-24
EP3443353B1 (en) 2024-03-13
RU2750035C2 (ru) 2021-06-21
IL262245B (en) 2021-03-25
SG11201808820QA (en) 2018-11-29
CN109154620A (zh) 2019-01-04
MX2018012580A (es) 2019-02-25
IL262245A (en) 2018-11-29
JP2019516966A (ja) 2019-06-20
US20190128900A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
EP3443353B1 (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
US9733261B2 (en) Methods and compositions for diagnosis and prognosis of stroke or other cerebral injury
US20130035603A1 (en) Troponin based rule-in and rule-out algorithm of myocardial infarction
JP2012132808A (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
US20240118292A1 (en) Levels of CSF-Seeded alpha-Synuclein Oligomers reflect Parkinson's Disease Severity
JP2023522066A (ja) 大血管閉塞により引き起こされる卒中についてのバイオマーカーとしてのd-ダイマー、グリア線維酸性タンパク質(gfap)、オステオプロテジェリン(opg)及びオステオポンチン(opn)
JP6113798B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
Badimón Maestro et al. Methods and kits for the diagnosis and risk stratification of patients with ischemia
US20160161499A1 (en) Sensitive diagnostic assay for inclusion body mysitis
JP6408087B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP6359158B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
HK40003205B (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
HK40003205A (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
US20110045504A1 (en) Prognostic Prediction Method for Acute Coronary Syndrome
EP2554995A1 (en) Troponin based rule in and rule out algorithm of myocardial infarction
JP6359160B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2016205740A1 (en) Methods and compositions for diagnosis and prognosis of appendicitis and differentiation of causes of abdominal pain
JP6193942B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
JP2012037349A (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いた認知機能障害疾患の検出方法
US8841084B2 (en) Methods for the detection and monitoring of acute myocardial infarction
JP6359159B2 (ja) 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
EP2385372A1 (en) Kidney disease in normal and abnormal pregnancy
JP2015017923A (ja) 糖尿病の病態進展を評価するためのバイオマーカー

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220329